PT-141 vs MT-2 Melanocortin Research Comparison: Receptor Selectivity & Profiles | Palmetto Peptides
PT-141 vs MT-2: Comparing Melanocortin Research Peptides Side by Side Research Notice: This article covers research on PT-141 and MT-2 — available from Palmetto Peptides for laboratory use only. Research Use Only Disclaimer: All peptides listed on this page ar
PT-141 vs MT-2: Comparing Melanocortin Research Peptides Side by Side
Research Notice: This article covers research on PT-141 and MT-2 — available from Palmetto Peptides for laboratory use only.
Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.
DISCLAIMER: This article is for educational and scientific research reference purposes only. All compounds discussed are not approved by the FDA for use in humans or animals. All data discussed here reflects preclinical animal research. Palmetto Peptides sells these compounds exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.
For background on this topic, see the Complete Guide to MT-2 Research Peptide from Palmetto Peptides.
Last Updated: May 14, 2026 | Reading Time: Approximately 10 minutes | Author: Palmetto Peptides Research Team
Quick Answer
PT-141 (bremelanotide) and MT-2 (Melanotan II) are both cyclic melanocortin peptide analogs derived from the alpha-MSH core, but they differ substantially in receptor selectivity and research profiles. MT-2 binds all five melanocortin receptor subtypes (MC1R through MC5R) with broad agonist activity, producing effects that include skin pigmentation, appetite suppression, and central signaling. PT-141 was specifically developed as a metabolite of MT-2 with reduced MC1R activity and a focus on MC3R/MC4R-mediated central effects, resulting in minimal pigmentation activity and a more CNS-targeted research profile.
The Melanocortin System: Research Context
The melanocortin system comprises five G protein-coupled receptors (MC1R-MC5R) and their endogenous ligands — primarily alpha-melanocyte stimulating hormone (alpha-MSH), beta-MSH, gamma-MSH, and ACTH — derived by proteolytic processing of the precursor protein pro-opiomelanocortin (POMC). These receptors are expressed in diverse tissues and regulate a wide range of biological functions, from skin pigmentation (MC1R) to energy homeostasis and feeding (MC3R, MC4R), sexual function (MC3R, MC4R), inflammation (MC1R, MC3R), and exocrine gland function (MC5R).
The endogenous melanocortin system is physiologically regulated not only by MSH peptide agonists but also by endogenous antagonists — agouti (a selective MC1R and MC4R antagonist) and agouti-related peptide (AgRP), which is an inverse agonist at MC3R and MC4R expressed in the arcuate nucleus and is the primary endogenous inhibitory regulator of the melanocortin pathway in energy balance. This built-in opponent regulation means that the melanocortin system functions as a balanced agonist/antagonist system, and pharmacological agonists like MT-2 and PT-141 compete with AgRP and agouti for receptor access.
Research with melanocortin receptor agonists and antagonists has been central to understanding obesity biology, pigmentation disorders, and central regulation of autonomic and reproductive functions. PT-141 and MT-2 represent two distinct points on the selectivity spectrum of this research.
MT-2 (Melanotan II): Broad-Spectrum Melanocortin Agonist
Melanotan II (MT-2) is a cyclic lactam analog of alpha-MSH with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The cyclic structure was introduced by researchers at the University of Arizona (Victor Hruby and colleagues) specifically to improve metabolic stability versus the linear alpha-MSH parent, which has a half-life of minutes in plasma. MT-2's disulfide-mimic lactam ring confers substantially improved plasma stability while maintaining broad melanocortin receptor agonist activity.
MT-2 binds all five melanocortin receptor subtypes with high affinity, though with different relative potencies. It is generally characterized as a non-selective melanocortin agonist, with nanomolar binding affinities at MC1R, MC3R, MC4R, and MC5R, and somewhat lower (but still active) affinity at MC2R (the ACTH receptor). This broad receptor engagement is what produces MT-2's multi-dimensional pharmacological profile in preclinical research.
MC1R activation by MT-2 in melanocytes drives melanin synthesis through the cAMP/PKA pathway, stimulating eumelanin (brown/black) over pheomelanin (red/yellow) production — producing the skin darkening effect that MT-2 is well-known for in animal models. This pigmentation effect is essentially absent from PT-141's profile, representing one of the clearest practical distinctions between the two compounds for researchers designing studies where skin pigmentation would confound or complicate experimental outcomes.
MT-2's MC4R agonism in the hypothalamus produces appetite-suppressing effects in rodent models — a finding that has contributed to the broader understanding of MC4R's role as a critical regulator of energy balance. MC4R loss-of-function mutations are among the most common monogenic causes of obesity in humans, and much of what is known about MC4R's anorectic role was established using compounds like MT-2 and other melanocortin agonists in animal models.
The detailed pharmacology and research applications of MT-2 are covered in the Melanotan II research peptide guide and the MT-2 mechanism of action article.
PT-141 (Bremelanotide): Selective CNS-Targeting Melanocortin Agonist
PT-141 (bremelanotide) emerged from research on MT-2 when investigators at Palatin Technologies observed that Melanotan II produced central effects that were not primarily pigmentation-related. PT-141 is the carboxylic acid form of MT-2 — specifically, it results from the hydrolysis of MT-2's lactam ring under physiological conditions, creating a ring-opened (linear) heptapeptide with the sequence Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH.
The structural difference between MT-2 (cyclic) and PT-141 (ring-opened, linear) has important consequences for receptor selectivity. The linear form of PT-141 has substantially reduced affinity at MC1R compared to the cyclic MT-2, while retaining good affinity at MC3R and MC4R. This selectivity shift away from MC1R and toward MC3R/MC4R is the molecular basis of PT-141's dramatically reduced pigmentation activity and its relatively maintained CNS-associated effects in animal models.
The central melanocortin effects mediated by MC3R and MC4R — the receptor subtypes most strongly retained in PT-141's binding profile — include effects on autonomic nervous system activity, energy balance, and aspects of centrally-regulated physiology that have been studied in the context of MC3R/MC4R function in the hypothalamus and brainstem.
The structure-activity relationships governing PT-141's receptor selectivity are explored in depth in the PT-141 structure-activity relationships article.
Researchers looking for a broader overview of this compound can refer to the Complete Guide to MT-2 Research Peptide, which covers the full research landscape in detail.
Receptor Binding Profile Comparison Table
MC1R
Melanocytes, macrophages, immune cells
Pigmentation, anti-inflammatory signaling
High (nanomolar Kd)
Substantially reduced vs MT-2
MC2R
Adrenal cortex (selective ACTH receptor)
Cortisol production regulation
Low-moderate
Low
MC3R
Hypothalamus (arcuate nucleus), brainstem, gut
Energy homeostasis, autonomic regulation, inflammation
Moderate-high (retained)
MC4R
Hypothalamus (PVN, VMH), spinal cord, brainstem
Appetite suppression, energy expenditure, autonomic outflow
MC5R
Exocrine glands (lacrimal, sebaceous), skeletal muscle
Exocrine gland secretion, immune modulation
Moderate
Key Structural and Pharmacokinetic Differences
The ring-opened versus cyclic structural distinction between PT-141 and MT-2 has pharmacokinetic consequences that researchers need to account for when designing comparison studies.
MT-2's cyclic lactam ring protects it from proteolytic degradation and confers superior plasma stability compared to linear peptides of similar length. MT-2's half-life in rodent plasma is in the range of 1-2 hours, which is substantially longer than native alpha-MSH (minutes) but shorter than many research peptides. PT-141 as a ring-opened linear peptide is more susceptible to enzymatic degradation than MT-2, though its N-terminal acetyl group and non-natural D-Phe residue provide some protection against aminopeptidase activity.
Both compounds are typically administered subcutaneously or intranasally in research studies. The intranasal route is particularly relevant for CNS-targeted research with these compounds, as it facilitates delivery via the olfactory and trigeminal nerve pathways to the CNS, bypassing the blood-brain barrier. The area postrema and other circumventricular organs also allow circulating melanocortin peptides to access CNS targets after systemic administration, which is thought to be an important route of central effect for systemically-administered MT-2.
Pigmentation Effects: Why the Difference Matters for Research Design
The practical consequence of MT-2's high MC1R activity is significant for experimental design: MT-2 treatment in lightly-pigmented rodents (e.g., Sprague-Dawley rats, C57BL/6 mice) produces visible skin darkening within days of initiation of chronic administration. This pigmentation effect:
Can confound behavioral assays that rely on visual observation of coat color (e.g., agouti gene expression studies)
Serves as a visual pharmacodynamic marker confirming MC1R engagement and compound activity
Is relevant to research on melanoma biology, melanocyte function, and photoprotection
May complicate blinding in non-pharmacological behavioral studies
PT-141's minimal MC1R activity eliminates this pigmentation confound, making it the preferred compound for CNS-focused research where skin color changes would be undesirable. Conversely, researchers specifically studying MC1R biology, melanocyte function, or the relationship between pigmentation and other melanocortin-regulated processes would find MT-2's MC1R activity essential to their experimental design.
Research Applications: Where Each Compound Fits
MT-2 in Current Research
MT-2 remains a valuable research tool for studies requiring broad melanocortin system engagement. Its high potency across multiple MCR subtypes makes it useful as a positive control in receptor characterization studies, and its reliable pigmentation effect in rodents provides a visual pharmacodynamic readout that PT-141 cannot supply. Researchers studying MC1R-mediated anti-inflammatory effects, melanocyte biology, or the interaction between pigmentation and metabolic regulation specifically require MT-2's MC1R activity.
The MT-2 buyer's guide and procurement context is available at the MT-2 buyers guide.
PT-141 in Current Research
PT-141's research profile centers on its CNS-targeted melanocortin effects, particularly through MC3R and MC4R. Researchers studying hypothalamic melanocortin signaling, energy balance, or autonomic CNS function prefer PT-141 when MC1R engagement would be confounding. The compound's reduced pigmentation activity makes behavioral studies cleaner and simplifies interpretation of results in paradigms where MC1R is not the receptor of interest.
Considerations for Receptor Selectivity Research
For researchers attempting to deconvolute the contributions of individual melanocortin receptor subtypes to observed effects, the differential selectivity of MT-2 and PT-141 provides a useful experimental tool. By comparing effects of MT-2 (pan-MCR agonist) versus PT-141 (reduced MC1R, maintained MC3R/MC4R) in the same animal model, researchers can generate hypotheses about which receptor subtype mediates specific observed endpoints. This comparison strategy is strengthened by also using receptor subtype-selective antagonists or receptor knockout animal models.
The melanocortin field has long relied on this comparative pharmacology approach — alpha-MSH analogs with progressive selectivity modifications (such as the gamma-MSH selective compounds targeting MC3R or the MC4R-selective analogs like MTII's close analogs) provide a toolkit for receptor attribution that is essential for mechanistic interpretation of in vivo data.
Frequently Asked Questions
Is PT-141 literally derived from MT-2, or are they separate syntheses?
PT-141 is structurally related to MT-2 — it corresponds to the ring-opened form of MT-2's lactam structure — but in research settings, both compounds are produced by independent synthesis rather than by hydrolyzing MT-2 in solution. The structural relationship reflects their shared research origin and explains the selectivity differences, but in practice, researchers source them as independent compounds with distinct characterization data. Each should have its own certificate of analysis confirming sequence identity, purity, and mass spectrometry data.
Which melanocortin receptor is most important for appetite-related research?
MC4R is the receptor most closely associated with appetite suppression and energy homeostasis in the hypothalamus. Loss-of-function MC4R mutations cause severe obesity in humans and rodents, and MC4R knockout mice become obese despite normal food quality availability. MC3R plays a supporting role — MC3R knockout mice show altered adiposity and altered sensitivity to high-fat diet but a milder obesity phenotype than MC4R knockouts. Both MT-2 and PT-141 are active at MC4R, making either compound relevant to appetite-focused research, though MT-2's broader receptor engagement means that MC1R, MC3R, and MC5R effects also need to be considered when interpreting results.
Do MT-2 and PT-141 have different half-lives?
Yes. MT-2's cyclic structure confers greater plasma stability than PT-141's linear form. MT-2 has a plasma half-life of approximately 1-2 hours in rodents. PT-141's half-life varies by formulation and route of administration but is generally somewhat shorter for the ring-opened linear form. Researchers should verify half-life data for their specific species and route of administration when designing timed dosing protocols or measuring PK/PD relationships.
Why does MT-2 produce pigmentation but PT-141 does not?
Skin pigmentation in response to melanocortin receptor agonism is mediated specifically through MC1R on melanocytes. MT-2's cyclic structure retains high-affinity binding to MC1R, stimulating eumelanin production in melanocytes. PT-141's ring-opened linear structure has substantially reduced affinity for MC1R — the structural change that accompanies ring opening alters the peptide's conformation in a way that reduces its fit into the MC1R binding site while preserving MC3R/MC4R engagement. This receptor selectivity shift is what eliminates most of the pigmentation effect.
Are there in vitro assays for comparing MT-2 and PT-141 receptor binding?
Yes. Standard approaches include radioligand competition binding assays using radiolabeled alpha-MSH or MTII at individual receptor subtypes expressed in HEK293 or CHO cell systems. Functional assays measuring cAMP accumulation downstream of MCR activation allow comparison of agonist potency (EC50) and efficacy (Emax) at each receptor subtype. These in vitro pharmacology tools are standard in melanocortin receptor research and allow precise quantification of the selectivity differences between MT-2 and PT-141 at each receptor subtype.
What is the endogenous ligand for MC4R and how does it compare to MT-2 and PT-141?
The primary endogenous agonist at MC4R is alpha-MSH, though beta-MSH and ACTH also show activity at MC4R. AgRP (agouti-related peptide) is an endogenous inverse agonist/antagonist at MC4R. Alpha-MSH has a very short plasma half-life (minutes) due to rapid aminopeptidase N cleavage. Both MT-2 and PT-141 were designed as more stable analogs with improved plasma stability, though through different structural strategies (cyclic lactam for MT-2, modified linear sequence for PT-141). At MC4R specifically, MT-2 has higher potency (lower EC50) than alpha-MSH, making it a super-agonist-like tool in receptor research settings.
Related PT-141 Research Articles
PT-141 vs Melanotan II: Comparative Analysis for Research Peptide Applications
PT-141 Structure-Activity Relationships: Molecular Modifications and Melanocortin Receptor Research
Optimal Storage Conditions and Stability of PT-141 Research Peptide in Laboratory Settings
Best Practices for Handling and Preparing PT-141 Research Peptide in the Lab
Using PT-141 in Radioligand Binding and Cell-Based Receptor Assays
Order research-grade PT-141 (Bremelanotide) with batch-specific COA from Palmetto Peptides. See also Melanotan II and our full research peptide catalog.
Peer-Reviewed Citations
Dorr RT, Lines R, Levine N, et al. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sciences. 1996;58(20):1777-1784.
Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides. 2006;27(4):921-930.
Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. "PT-141: a melanocortin agonist for the treatment of sexual dysfunction." Annals of the New York Academy of Sciences. 2003;994:96-102.
Cone RD. "Anatomy and regulation of the central melanocortin system." Nature Neuroscience. 2005;8(5):571-578.
Hruby VJ, Lu D, Sharma SD, Castrucci AL, Kesterson RA, al-Obeidi FA, Cone RD. "Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-c[Asp5,D-Phe7,Lys10] alpha-MSH(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors." Journal of Medicinal Chemistry. 1995;38(18):3454-3461.
Final Disclaimer: All compounds discussed are research chemicals not approved by the FDA for human or veterinary use. All content here is for scientific and educational reference only. Palmetto Peptides sells these products exclusively for in vitro and preclinical laboratory research.
Authored by the Palmetto Peptides Research Team | Last Updated: May 14, 2026
Related Research
Complete Guide to MT-2 Research Peptide
Mechanism of Action of MT-2 Research Peptide in Melanocortin Receptor Studies
Current Research Applications of MT-2 Peptide in Scientific Cell and Receptor Studies
Step-by-Step Reconstitution of MT-2 Research Peptide for Laboratory Experiments